Dear Spiral user, We’re pleased to introduce Helix, https://helix.imperial.ac.uk/ Imperial’s new repository for research datasets. Please use Helix for all future dataset deposits. There is no change to Spiral - continue depositing as usual. For queries, contact the Research Data Management team at rdm-enquiries@imperial.ac.uk. Kind regards, the Spiral Team. The Spiral team
Calcium channel antagonists as disease-modifying therapy for Parkinson's disease: therapeutic rationale and current status
File(s)
SWART_&_HURLEY_final.pdf (526.83 KB)
Accepted version
Author(s)
Swart, T
Hurley, MJ
Type
Journal Article
Abstract
Parkinson's disease is a disabling hypokinetic neurological movement disorder in which the aetiology is unknown in the majority of cases. Current pharmacological treatments, though effective at restoring movement, are only symptomatic and do nothing to slow disease progression. Electrophysiological, epidemiological and neuropathological studies have implicated CaV1.3 subtype calcium channels in the pathogenesis of the disorder, and drugs with some selectivity for this ion channel (brain-penetrant dihydropyridine calcium channel blockers) are neuroprotective in animal models of the disease. Dihydropyridines have been safely used for decades to treat hypertension and other cardiovascular disorders. A phase II clinical trial found that isradipine was safely tolerated by patients with Parkinson's disease, and a phase III trial is currently underway to determine whether treatment with isradipine is neuroprotective and therefore able to slow the progression of Parkinson's disease. This manuscript reviews the current information about the use of dihydropyridines as therapy for Parkinson's disease and discusses the possible mechanism of action of these drugs, highlighting CaV1.3 calcium channels as a potential therapeutic target for neuroprotection in Parkinson's disease.
Date Issued
2016-11-08
Date Acceptance
2016-11-01
Citation
CNS Drugs, 2016, 30 (12), pp.1127-1135
URI
DOI
ISSN
1172-7047
Publisher
Springer
Start Page
1127
End Page
1135
Journal / Book Title
CNS Drugs
Volume
30
Issue
12
Copyright Statement
© Springer-Verlag 2016. The final publication is available at Springer via http://dx.doi.org/10.1007/s40263-016-0393-9
Identifier
http://www.ncbi.nlm.nih.gov/pubmed/27826740
PII: 10.1007/s40263-016-0393-9
Subjects
Psychiatry
1115 Pharmacology And Pharmaceutical Sciences
1109 Neurosciences
Publication Status
Published
Coverage Spatial
New Zealand